Mainz Biomed N.V., a molecular genetics diagnostic company, has announced a collaborative agreement with Thermo Fisher Scientific to accelerate the development and commercialization of its next-generation colorectal cancer (CRC) screening product.   The partnership will leverage Thermo Fisher’s advanced technologies and expertise to enhance Mainz Biomed’s mRNA-based CRC screening test. This non-invasive test, which has shown promising results in clinical trials, aims to detect both early-stage...